Last updated: 2026-09-04 22:49:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
CareDx, Inc. (CDNA) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $50.83, with a market capitalisation of $2.57B and a P/E ratio of 23.24. Over the past 52 weeks, its price has ranged from $12.37 to $53.67. This page covers its latest market performance, valuation, price trends and company information.
$2.57B | |
$49.73 | |
$99.83 | |
$0.76 | |
$49.86 | |
890.60K | |
-- | |
23.24 | |
$53.67 | |
$12.37 | |
-- | |
-- |
CareDx, Inc. (CDNA) is trading at $50.30 in after-hours trading as of 2026-09-04 22:14:00, up 0.87% ($0.44) from the regular-session close of $49.86.
After-hours trading shows how investors are pricing CDNA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, CareDx, Inc. (CDNA) moved from $49.16 to $50.83, representing a gain of 3.39% ($1.67).
The stock traded between $48.81 and $51.22 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.14 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 93.1%
CDNA is currently trading at $50.83, placing it 93.1% of the way from its 52-week low of $12.37 to its 52-week high of $53.67. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 765 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CareDx, Inc. (CDNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.